RxDoctor Payments Data

George Graham, MD

Cardiovascular Disease · Metairie, LANPI 1871021279

Payments from drug & device makers

$3,431in general payments, 2019–2025

Across 102 payments — averaging $33.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$433
  • Abbott$316
  • Philips North America LLC$306
  • Amgen$261
  • Johnson & Johnson$249
  • Abiomed$238
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$3,430100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,431 in reported general payments places this provider in the 50th percentile of 281 cardiovascular disease providers in Louisiana.

See all cardiovascular disease providers in Louisiana

Medicare billing

Part B allowed, 2024
$80,538
Medicare patients
863
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban153$189,215
EntrestoSacubitril/Valsartan41$50,459
JardianceEmpagliflozin22$25,122
Repatha SureclickEvolocumab16$18,826
Metoprolol Succinate272$3,285
Bumetanide53$2,201
Rosuvastatin Calcium173$1,392
Atorvastatin Calcium126$1,151
Midodrine Hcl12$1,051
Valsartan23$814
Lisinopril86$580
Ranolazine ErRanolazine20$557
Flecainide Acetate15$481
Amlodipine Besylate173$447
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$38$189,215153 claims
NovartisEntresto$114$50,45941 claims
Boehringer IngelheimJardiance$76$25,12222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 281 cardiovascular disease providers in Louisiana.

Other cardiovascular disease in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →